In this study, we investigated the effect of Didox (DX) on the pathogenicity of and host responses to murine cytomegalovirus (MCMV) infection.
Methods
In vitro efficacy of DX against MCMV was determined using plaque reduction assays. For in vivo studies, mice infected with a sublethal dose (104 PFU) of MCMV were treated daily with DX (200 mg/kg) using either a prophylactic or delayed protocol. At predetermined intervals, target organs were removed for histopathology. Cytokine transcription and viral load were performed using real-time PCR. Serum cytokine levels were determined by ELISA, and T-cell markers by realtime PCR.
Results
DX (0.5–50 μM) inhibited MCMV plaque formation in vitro. However, in vivo, prophylactic DX treatment did not decrease viral load and prolonged hepatic proinflammatory cytokine transcription at days 3 and 5 post-infection, which corresponded with more severe histopathological changes observed in the liver. Significant CD8+ T-cell marker suppression was seen, in accordance with DX-induced inhibition of lymphocyte proliferation observed in vitro. DX prolonged the recovery of MCMV- infected mice when given after infection was established.
Conclusions
Despite promising MCMV inhibition in vitro, DX had no beneficial effect on MCMV disease in our model and paradoxically had adverse effects when administered prophylactically. The lack of correlation between in vitro activity and in vivo efficacy emphasizes the importance of selecting appropriate antiviral targets and of using animal models when testing new drugs.
References
1.
ChouS.W.Cytomegalovirus drug resistance and clinical implications. Transpl Infect Dis2001; 3Suppl 2: 20–24.
2.
ShaoJ., ZhouB., ChuB., YenY.Ribonucleotide reductase inhibitors and future drug design. Curr Cancer Drug Targets2006; 6: 409–431.
3.
LemboD., DonalisioM., HoferA.The ribonucleotide reductase R1 homolog of murine cytomegalovirus is not a functional enzyme subunit but is required for pathogenesis. J Virol2004; 78: 4278–4288.
4.
TihanT., ElfordH.L., CoryJ.G.Studies on the mechanisms of inhibition of L1210 cell growth by 3,4-dihydroxybenzohydroxamic acid and 3,4-dihydroxybenzamidoxime. Adv Enzyme Regul1991; 31: 71–83.
5.
Fritzer-SzekeresM., NovotnyL., VachalkovaA., FindenigG., ElfordH.L., SzekeresT.Iron binding capacity of didox (3,4-dihydroxybenzohydroxamic acid) and amidox (3,4-dihydroxybenzamidoxime) new inhibitors of the enzyme ribonucleotide reductase. Life Sci1997; 61: 2231–2237.
6.
ElfordH., Van't RietB.The inhibition of nucleoside diphosphate reductase by hydroxbenzohydroxamic acid derivatives. Pharmacol Ther1985; 29: 239–254.
7.
ElfordH.L., WamplerG.L., van't RietB.New ribonucleotide reductase inhibitors with antineoplastic activity. Cancer Res1979; 39: 844–851.
8.
TurchanJ., PocernichC.B., GairolaC.Oxidative stress in HIV demented patients and protection ex vivo with novel antioxidants. Neurology2003; 60: 307–314.
9.
MayhewC.N., SumpterR., InayatM.Combination of inhibitors of lymphocyte activation (hydroxyurea, trimidox, and didox) and reverse transcriptase (didanosine) suppresses development of murine retrovirus-induced lymphoproliferative disease. Antiviral Res2005; 65: 13–22.
10.
PomeroyC., HillerenP.J., JordanM.C.Latent murine cytomegalovirus DNA in splenic stromal cells of mice. J Virol1991; 65: 3330–3334.
11.
El-AmouriI.S., Bani-AhmadM., Tang-FeldmanY.Increased morbidity and mortality in murine cytomegalovirus-infected mice following allogeneic bone marrow transplant is associated with reduced surface decay accelerating factor expression. Clin Exp Immunol2010; 162: 379–391.
12.
Tang-FeldmanY.J., WojtowiczA., LochheadG.R., HaleM.A., LiY., PomeroyC.Use of quantitative real-time PCR (qRT-PCR) to measure cytokine transcription and viral load in murine cytomegalovirus infection. J Virol Methods2006; 131: 122–129.
13.
KiparA., LeuteneggerC.M., HetzelU.Cytokine mRNA levels in isolated feline monocytes. Vet Immunol Immunopathol2001; 78: 305–315.
14.
RitterJ.T., Tang-FeldmanY.J., LochheadG.R.In vivo characterization of cytokine profiles and viral load during murine cytomegalovirus-induced acute myocarditis. Cardiovasc Pathol2010; 19: 83–93.
15.
VliegenI., HerngreenS., GraulsG., BruggemanC., StassenF.Improved detection and quantification of mouse cytomegalovirus by real-time PCR. Virus Res2003; 98: 17–25.
16.
DesmetV.J.Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. J Hepatol2003; 38: 382–386.
17.
KnodellR.G., IshakK.G., BlackW.C.Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology1981; 1: 431–435.
18.
PomeroyC., DelongD., ClabotsC., RiciputiP., FiliceG.A.Role of interferon-gamma in murine cytomegalovirus infection. J Lab Clin Med1998; 132: 124–133.
19.
GeistL.J., HindeS.L.Susceptibility to cytomegalovirus infection may be dependent on the cytokine response to the virus. J Investig Med2001; 49: 434–441.
20.
OrangeJ.S., BironC.A.Characterization of early IL-12, IFN-alphabeta, and TNF effects on antiviral state and NK cell responses during murine cytomegalovirus infection. J Immunol1996; 156: 4746–4756.
21.
OrangeJ.S., BironC.A.An absolute and restricted requirement for IL-12 in natural killer cell IFN-gamma production and antiviral defense. Studies of natural killer and T cell responses in contrasting viral infections. J Immunol1996; 156: 1138–1142.
22.
PavićI., PolicB., CrnkovicI., LucinP., JonjicS., KoszinowskiU.H.Participation of endogenous tumour necrosis factor alpha in host resistance to cytomegalovirus infection. J Gen Virol1993; 74: 2215–2223.
23.
van der MeerJ.W., RubinR.H., PasternackM., MedearisD.N., LynchP., DinarelloC.A.The in vivo and in vitro effects of interleukin-1 and tumor necrosis factor on murine cytomegalovirus infection. Biotherapy1989; 1: 227–231.
24.
InayatM.S., El-AmouriI.S., Bani-AhmadM., ElfordH.L., GallicchioV.S., OakleyO.R.Inhibition of allogeneic inflammatory responses by the ribonucleotide reductase inhibitors, Didox and Trimidox. J Inflamm (Lond)2010; 7: 43.
SpectorT., AverettD.R., NelsonD.J.Potentiation of antiherpetic activity of acyclovir by ribonucleotide reductase inhibition. Proc Natl Acad Sci U S A1985; 82: 4254–4257.
27.
SpectorT., JonesT.E.Herpes simplex type 1 ribonucleotide reductase. Mechanism studies with inhibitors. J Biol Chem1985; 260: 8694–8697.
28.
WakisakaN., YoshizakiT., Raab-TraubN., PaganoJ.S.Ribonucleotide reductase inhibitors enhance cidofovir-induced apoptosis in EBV-positive nasopharyngeal carcinoma xenografts. Int J Cancer2005; 116: 640–645.
29.
NeytsJ., De ClercqE.Hydroxyurea potentiates the antiherpesvirus activities of purine and pyrimidine nucleoside and nucleoside phosphonate analogs. Antimicrob Agents Chemother1999; 43: 2885–2892.
30.
LemboD., AngerettiA., GariglioM., LandolfoS.Murine cytomegalovirus induces expression and enzyme activity of cellular dihydrofolate reductase in quiescent cells. J Gen Virol1998; 79: 2803–2807.
31.
LemboD., GribaudoG., HoferA.Expression of an altered ribonucleotide reductase activity associated with the replication of murine cytomegalovirus in quiescent fibroblasts. J Virol2000; 74: 11557–11565.
32.
NavarraP., TringaliG., PreziosiP.The effects of inhibitors of cyclo-oxygenase, lipoxygenase and nitric oxide synthase pathways on the toxicity of hydroxyurea in adrenalectomized rats. Toxicol Lett1996; 86: 13–18.
